🇺🇸 Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose in United States

Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose (variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in United States

Frequently asked questions

Is Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose cost in United States?

annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.